At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Aug 12, 2026 at 07:00 ET
Sutro Biopharma reported Q2 2026 revenue of $9.8M (down 84.6% YoY from $63.7M) and a net loss of $38.5M (-$2.33 EPS), significantly worse than the consensus estimate of -$2.27 EPS. The revenue decline reflects the absence of large upfront collaboration payments that boosted the prior-year period. However, the filing's primary market-moving content is the early clinical data for STRO-004, showing confirmed partial responses and a favorable tolerability profile, which validates the platform and supports pipeline progression despite the weak financials.
- Q2 2026 revenue was $9.8M, down 84.6% from $63.7M in Q2 2025, driven by the absence of large upfront collaboration payments.
- Net loss widened to $38.5M (-$2.33 EPS) vs. $11.5M (-$1.35 EPS) a year ago, missing consensus EPS of -$2.27.
- Cash, cash equivalents and marketable securities were $164.3M as of June 30, 2026, down from $202.6M at March 31, 2026.
- STRO-004 Phase 1 data showed confirmed and unconfirmed partial responses across three tumor types with a favorable tolerability profile; dose optimization ongoing at 4-5 mg/kg.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access